Search
for
Sort by
Research 30 of 1000+
- Novel Clove Essential Oil Nanoemulgel Tailored by Taguchi’s Model and Scaffold-Based Nanofibers: Phytopharmaceuticals with Promising Potential as Cyclooxygenase-2 Inhibitors in External Inflammation
- Mimosine Dipeptide Enantiomsers: Improved Inhibitors against Melanogenesis and Cyclooxygenase
- Aqueous extract of Asiasari radix inhibits formalin-induced hyperalgesia via NMDA receptors
- Maternal PPARγ protects nursing neonates by suppressing the production of inflammatory milk
- Liquid Chromatography-Mass Spectrometry-Based In Vitro Metabolic Profiling Reveals Altered Enzyme Expressions in Eicosanoid Metabolism
- Cyclooxygenases in the skin: pharmacological and toxicological implications
- Role of distinct fibroblast lineages and immune cells in dermal repair following UV radiation induced tissue damage
- Clinical Snippets
- Metabolic pathways of eicosanoids—derivatives of arachidonic acid and their significance in skin
- Expression of Cyclooxygenase Isozymes During Morphogenesis and Cycling of Pelage Hair Follicles in Mouse Skin: Precocious Onset of the First Catagen Phase and Alopecia upon Cyclooxygenase-2 Overexpression
- Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
- Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression
- The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
- Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
- Deciphering the Skin Anti-Aging and Hair Growth Promoting Mechanisms of Opophytum forskahlii Seed Oil via Network Pharmacology
- A new target for squamous cell skin cancer?
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Contemporary drug synthesis
- Clin-Alert
- News in brief
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- New insights into the functions of Cox-2 in skin and esophageal malignancies
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- Dual inhibitors of urease and carbonic anhydrase-II from <i>Iris</i> species
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase inhibitors in dermatology: a review
- Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study